Compare Stocks

→ The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXLA Axcella Health	$0.40 -8.9%	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	6,700 shs
IKT Inhibikase Therapeutics	$1.36 +3.8%	$1.99	$0.79 ▼ $4.35	$8.81M	1.31	116,203 shs	9,931 shs
ONVO Organovo	$0.95 +3.3%	$1.03	$0.85 ▼ $2.05	$9.55M	0.87	750,262 shs	82,095 shs
PALI Palisade Bio	$6.22 -7.3%	$5.91	$3.82 ▼ $36.60	$5.85M	1.25	879,944 shs	22,205 shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	-96.13%
IKT Inhibikase Therapeutics	0.00%	-5.76%	-40.18%	-48.83%	-64.37%
ONVO Organovo	0.00%	-10.29%	-8.52%	-17.50%	-49.78%
PALI Palisade Bio	0.00%	-13.31%	+62.86%	-0.81%	-71.87%

The Crypto 9-5 Escape Plan (Ad)

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	1.6765 of 5 stars	3.5	0.0	0.0	0.0	0.6	1.7	1.3
ONVO Organovo	0.5226 of 5 stars	0.0	3.0	0.0	0.0	2.9	0.0	1.3
PALI Palisade Bio	1.6023 of 5 stars	3.5	2.0	0.0	0.0	2.9	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXLA Axcella Health	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	3.00	Buy	$27.00	1,885.29% Upside
ONVO Organovo	N/A	N/A	N/A	N/A
PALI Palisade Bio	3.00	Buy	$131.25	2,010.13% Upside

Current Analyst Ratings

Latest PALI, AXLA, ONVO, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/1/2024	PALI Palisade Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.50
4/16/2024	PALI Palisade Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.50
3/5/2024	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 5/13/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXLA Axcella Health	N/A	N/A	N/A	N/A	$1.42 per share	N/A
IKT Inhibikase Therapeutics	$260K	33.90	N/A	N/A	$1.78 per share	0.76
ONVO Organovo	$370K	25.81	N/A	N/A	$1.76 per share	0.54
PALI Palisade Bio	$250K	23.39	N/A	N/A	$18.29 per share	0.34

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXLA Axcella Health	-$81.19M	-$19.25	N/A	∞	N/A	N/A	N/A	-259.91%	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$3.56	N/A	N/A	N/A	-5,886.15%	-107.54%	-91.82%	5/20/2024 (Estimated)
ONVO Organovo	-$17.26M	-$2.17	N/A	N/A	N/A	N/A	-182.88%	-138.52%	7/11/2024 (Estimated)
PALI Palisade Bio	-$12.30M	-$27.14	N/A	∞	N/A	N/A	-89.68%	-76.18%	N/A

Latest PALI, AXLA, ONVO, and IKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	IKT Inhibikase Therapeutics	-$0.78	-$0.63	+$0.15	-$0.63	N/A	N/A
3/26/2024	Q4 2023	PALI Palisade Bio	N/A	-$3.75	-$3.75	-$3.75	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
ONVO Organovo	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXLA Axcella Health	N/A	0.80	0.80
IKT Inhibikase Therapeutics	N/A	4.13	4.13
ONVO Organovo	N/A	3.67	3.67
PALI Palisade Bio	N/A	5.15	5.15

Ownership

Institutional Ownership

Company	Institutional Ownership
AXLA Axcella Health	65.07%
IKT Inhibikase Therapeutics	3.81%
ONVO Organovo	8.23%
PALI Palisade Bio	11.79%

Insider Ownership

Company	Insider Ownership
AXLA Axcella Health	2.20%
IKT Inhibikase Therapeutics	20.30%
ONVO Organovo	5.00%
PALI Palisade Bio	2.24%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AXLA Axcella Health	11	2.95 million	2.88 million	Optionable
IKT Inhibikase Therapeutics	8	6.48 million	5.16 million	Not Optionable
ONVO Organovo	18	10.04 million	9.54 million	Optionable
PALI Palisade Bio	9	940,000	917,000	Not Optionable

PALI, AXLA, ONVO, and IKT Headlines

Recent News About These Companies

May 7, 2024 | globenewswire.com

Palisade Bio Appoints Margery Fischbein to its Board of Directors

May 7, 2024 | globenewswire.com

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

May 3, 2024 | americanbankingnews.com

Maxim Group Reiterates "Buy" Rating for Palisade Bio (NASDAQ:PALI)

May 2, 2024 | globenewswire.com

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

May 1, 2024 | msn.com

Marijuana reclassified federally in major win for the legal cannabis industry

May 1, 2024 | msn.com

Palisade Bio stock rallies 50% premarket on colitis drug update

May 1, 2024 | finance.yahoo.com

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

May 1, 2024 | globenewswire.com

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

April 23, 2024 | msn.com

Palisade Bio, Strand Life Sciences team up on colitis drug research

April 23, 2024 | invezz.com

Palisade Bio stock rallies on Strand Life Sciences partnership

April 23, 2024 | msn.com

Why Palisade Bio Stock Is Up Today

April 23, 2024 | finance.yahoo.com

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

April 23, 2024 | globenewswire.com

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

April 19, 2024 | benzinga.com

Looking Into Palisade Bio's Recent Short Interest

April 18, 2024 | bioworld.com

Palisade Bio shows successful bioactivation of prodrug PALI-2108 into its active PDE4 inhibitor form

April 18, 2024 | pharmabiz.com

Palisade Bio completes its analysis evaluating ex-vivo bioactivation of PALI-2108 for patients affected by ulcerative colitis

April 17, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Palisade Bio (PALI)

April 17, 2024 | msn.com

How Apple Car Key Works (and Why It Still Hasn’t Caught On)

April 16, 2024 | investorideas.com

Biopharma Stocks in Play - Palisade Bio, Inc. (Nasdaq: PALI) Soars on News it Demonstrated Bioactivation of PALI-2108 In Ex-Vivo Study

April 16, 2024 | msn.com

Palisade Bio stock rallies nearly 100% on colitis drug analysis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Axcella Health

NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Inhibikase Therapeutics

NYSE:IKT

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Organovo

NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Palisade Bio

NASDAQ:PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial